Proton pump inhibitor administration via nasogastric tube in pediatric practice: Comparative analysis with protocol optimization

International Journal of Pharmaceutics

Volumn 390, Issue 2, 2010, Pages 160-164

  Ponrouch, M P ^a   Sautou Miranda, V ^a,b   Boyer, A ^a,b   Bourdeaux, D ^a   Montagner, A ^a   Chopineau, J ^a,b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Children; Nasogastric tube; Proton pump inhibitor

Indexed keywords

DILUENT; ESOMEPRAZOLE; INEXIUM; LANSOPRAZOLE; OGASTORO; OMEPRAZOLE; POLYURETHAN; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; NASOGASTRIC TUBE; PEDIATRICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RELIABILITY; REPRODUCIBILITY; SUSPENSION; TABLET; TABLET DISINTEGRATION; TUBE FLOW; ULTRAVIOLET SPECTROPHOTOMETRY; WATER CONTENT;

CHILD; DRUG DELIVERY SYSTEMS; HUMANS; INTUBATION, GASTROINTESTINAL; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS; RHEOLOGY; SPECTRUM ANALYSIS; WATER;

EID: 77951498246     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.01.040     Document Type: Article

References (14)

1. Barron J.J., Tan H., Spalding J., Bakst A.W., Singer J. Proton pump inhibitor utilization patterns in infants. J. Pediatr. Gastroenterol. Nutr. 2007, 45:421-427.
2. Chun A.H., Shi H.H., Achari R., Dennis S., Cavanaugh J.H. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin. Ther. 1996, 18:833-842.
3. Devlin J.W., Bakshi A., Bungat K., Olsen K.M. An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube. Aliment. Pharmacol. Ther. 2006, 24:1603-1611.
4. Doan T.T., Wang Q., Griffin J.S., Lukasik N.L., O'Dea R.F., Pan W.J. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am. J. Health Syst. Pharm. 2001, 58:1512-1519.
5. Faure C. Indications for proton pump inhibitors. Arch. Pédiatr. 2004, 11:674-676.
6. Freston J., Chiu Y.L., Pan W.J., Lukasik N., Taubel J. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Am. J. Gastroenterol. 2001, 96:2058-2065.
7. Lang L. FDA approves Nexium for use in children 1-11 years. Gastroenterology 2008, 134:1282.
8. Messaouik D., Sautou-Miranda V., Chopineau J. Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube. Int. J. Pharm. 2005, 299:65-72.
9. Reilly J.P. Safety profile of the proton pump inhibitors. Am. J. Health Syst. Pharm. 1999, 56(Suppl. 4):S11-S17.
10. Shah S.A., Sander S., Coleman C.I., White C.M. Delivery of esomeprazole magnesium through nasogastric tube and gastrostomy tubes using an oral liquid vehicle as a suspending agent in vitro. Am. J. Health Syst. Pharm. 2006, 63:1882-1887.
11. Song J.C., Quercia R.A., Fan C., Tsikouris J., White M. Pharmacokinetics comparison of omeprazole capsules and a simplified omeprazole in children. Dig. Dis. Sci. 1999, 44:134-139.
12. Sostek M.B., Chen Y., Skammer W., Winter H., Zhao J., Anderson T. Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing. Aliment. Pharmacol. Ther. 2003, 18:581-586.
13. Tolia V., Boye R.K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig. Dis. Sci. 2008, 53:385-393.
14. White C.M., Kalus J.S., Quercia R., Fortier C., Piotrowski A., Roach A., Sostek M.B. Delivery of esomeprazole magnesium enteric coated pellets through small caliber and standard nasogastric tubes and gastrostomy tubes in vitro. Am. J. Health Syst. Pharm. 2002, 59:2085-2088.